Table 1 Baseline data in the derivation and validation cohort
Characteristic | Women | Men | ||
|---|---|---|---|---|
Derivation cohort N = 989,732 | Validation cohort N = 494,865 | Derivation cohort N = 946,784 | Validation cohort N = 473,392 | |
Smoking status recorded | 789,562 (79.8) | 394,819 (79.8) | 651,127 (68.8) | 325,555 (68.8) |
Body mass index (BMI) recorded | 716,715 (72.4) | 358,418 (72.4) | 552,983 (58.4) | 276,680 (58.4) |
Total cholesterol to HDL cholesterol ratio recorded | 149,188 (15.1) | 74,602 (15.1) | 142,013 (15.0) | 70,741 (14.9) |
Systolic blood pressure (SBP) recorded | 821,768 (83.0) | 410,765 (83.0) | 620,788 (65.6) | 310,112 (65.5) |
2 or more SBP readings recorded before baseline | 525,966 (53.1) | 262,696 (53.1) | 245,671 (25.9) | 122,884 (26.0) |
Complete data for BMI, total to HDL cholesterol ratio, SBP, and smoking status | 95,886 (9.7) | 47,996 (9.7) | 79,081 (8.4) | 39,496 (8.3) |
Age (years) | 46.0 (15.3) | 46.0 (15.3) | 44.8 (13.9) | 44.8 (13.9) |
Townsend score | − 0.6 (2.8) | − 0.6 (2.8) | − 0.5 (2.8) | − 0.5 (2.8) |
BMI (kg/m2) | 25.9 (5.7) | 25.9 (5.7) | 26.6 (4.7) | 26.6 (4.7) |
Total cholesterol to HDL cholesterol ratio | 3.7 (1.1) | 3.7 (1.1) | 4.4 (1.3) | 4.4 (1.3) |
Systolic blood pressure (mmHg) | 125.4 (18.0) | 125.4 (18.0) | 131.1 (16.2) | 131.1 (16.2) |
Systolic blood pressure variability | 10.0 (5.7) | 9.9 (5.7) | 10.3 (6.2) | 10.3 (6.2) |
Ethnicity | ||||
Ethnicity recorded | 783,626 (79.2) | 391,224 (79.1) | 610,093 (64.4) | 305,385 (64.5) |
White or not recorded | 908,817 (91.8) | 454,329 (91.8) | 891,002 (94.1) | 445,219 (94.0) |
Indian | 15,045 1.5) | 7443 (1.5) | 10,182 (1.1) | 5140 (1.1) |
Pakistani | 6411 (0.6) | 3139 (0.6) | 4452 (0.5) | 2222 (0.5) |
Bangladeshi | 1717 (0.2) | 877 (0.2) | 1403 (0.1) | 742 (0.2) |
Other Asian | 9027 0.9) | 4670 (0.9) | 6636 (0.7) | 3337 (0.7) |
Black Caribbean | 6369 (0.6) | 3136 (0.6) | 4455 (0.5) | 2232 (0.5) |
Black African | 12,420 (1.3) | 6384 (1.3) | 8535 (0.9) | 4287 (0.9) |
Chinese | 4390 (0.4) | 2349 (0.5) | 2325 (0.2) | 1178 (0.2) |
Other | 25,536 (2.6) | 12,538 (2.5) | 17,794 (1.9) | 9035 (1.9) |
Smoking status | ||||
Non-smoker | 471,885 (59.8) | 235,889 (59.7) | 318,933 (49.0) | 159,738 (49.1) |
Former smoker | 144,631 (18.3) | 72,773 (18.4) | 144,517 (22.2) | 72,366 (22.2) |
Light smoker | 56,913 (7.2) | 28,364 (7.2) | 50,254 (7.7) | 25,006 (7.7) |
Moderate smoker | 74,332 (9.4) | 37,358 (9.5) | 74,919 (11.5) | 37,492 (11.5) |
Heavy smoker | 41,801 (5.3) | 20,435 (5.2) | 62,504 (9.6) | 30,953 (9.5) |
Family history of coronary heart disease in 1st degree relative < 60 years | 65,264 (6.6) | 32,360 (6.5) | 50,139 (5.3) | 25,098 (5.3) |
Type 1 diabetes | 2512 (0.3) | 1240 (0.3) | 3227 (0.3) | 1616 (0.3) |
Type 2 diabetes | 11,336 (1.1) | 5686 (1.1) | 14,147 (1.5) | 6930 (1.5) |
Treated hypertension | 77,148 (7.8) | 38,796 (7.8) | 55,397 (5.9) | 27,371 (5.8) |
Rheumatoid arthritis | 8510 (0.9) | 4192 (0.8) | 3111 (0.3) | 1613 (0.3) |
Atrial fibrillation | 5412 (0.5) | 2787 (0.6) | 7058 (0.7) | 3562 (0.8) |
Chronic kidney disease (stage 3, 4, or 5) | 4636 (0.5) | 2282 (0.5) | 3789 (0.4) | 1870 (0.4) |
Migraine | 78,530 (7.9) | 39,162 (7.9) | 27,765 (2.9) | 13,706 (2.9) |
Corticosteroid use | 13,887 (1.4) | 6787 (1.4) | 7833 (0.8) | 3991 (0.8) |
HIV/AIDS | 206 (0.0) | 83 (0.0) | 264 (0.0) | 181 (0.0) |
Systemic lupus erythematosus | 1149 (0.1) | 576 (0.1) | 108 (0.0) | 57 (0.0) |
Atypical antipsychotic use | 5663 (0.6) | 2806 (0.6) | 5511 (0.6) | 2825 (0.6) |
Severe mental illness | 73,909 (7.5) | 36,890 (7.5) | 38,202 (4.0) | 19,062 (4.0) |
Erectile dysfunction diagnosis or treatment | NA (NA) | NA (NA) | 26,099 (2.8) | 13,165 (2.8) |
Charlson comorbidity index score | ||||
0 | 791,395 (80.0) | 396,570 (80.1) | 781,665 (82.6) | 391,400 (82.7) |
1 | 153,590 (15.5) | 76,061 (15.4) | 134,497 (14.2) | 66,703 (14.1) |
2 | 34,250 (3.5) | 17,045 (3.4) | 23,133 (2.4) | 11,532 (2.4) |
3+ | 10,497 (1.1) | 5189 (1.0) | 7489 (0.8) | 3757 (0.8) |